Oncolys Biopharma Inc logo

4588 - Oncolys Biopharma Inc Share Price

¥1660 12.0  0.7%

Last Trade - 7:00am

Sector
Healthcare
Size
Small Cap
Market Cap £178.0m
Enterprise Value £160.0m
Revenue £10.0m
Position in Universe 1626th / 3869
Bullish
Bearish
Unlock 4588 Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Oncolys Biopharma Inc revenues increased 45% to Y70.3M. Net loss applicable to common stockholders decreased 21% to Y286M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Test drug business segment loss decrease of 86% to Y13M, Pharmaceutical business segment loss decrease of 17% to Y99.6M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

4588 Revenue Unlock 4588 Revenue

Net Income

4588 Net Income Unlock 4588 Revenue

Normalised EPS

4588 Normalised EPS Unlock 4588 Revenue

PE Ratio Range

4588 PE Ratio Range Unlock 4588 Revenue

Dividend Yield Range

4588 Dividend Yield Range Unlock 4588 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
4588 EPS Forecasts Unlock 4588 Revenue
Profile Summary

Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated March 18, 2004
Public Since December 6, 2013
No. of Shareholders: 15,605
No. of Employees: 27
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Tokyo Stock Exchange
Shares in Issue 14,317,269
Free Float (0.0%)
Eligible for
ISAs
SIPPs
4588 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 4588
Upcoming Events for 4588
Monday 29th June, 2020
Dividend For 4588.T - 0.0000 JPY
Frequently Asked Questions for Oncolys Biopharma Inc
What is the Oncolys Biopharma Inc share price?

As of 7:00am, shares in Oncolys Biopharma Inc are trading at ¥1660, giving the company a market capitalisation of £178.0m. This share price information is delayed by 15 minutes.

How has the Oncolys Biopharma Inc share price performed this year?

Shares in Oncolys Biopharma Inc are currently trading at ¥1660 and the price has moved by -23.99% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oncolys Biopharma Inc price has moved by -27.24% over the past year.

What are the analyst and broker recommendations for Oncolys Biopharma Inc?

Of the analysts with advisory recommendations for Oncolys Biopharma Inc, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Oncolys Biopharma Inc is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Oncolys Biopharma Inc next release its financial results?

Oncolys Biopharma Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Oncolys Biopharma Inc dividend yield?

Oncolys Biopharma Inc does not currently pay a dividend.

Does Oncolys Biopharma Inc pay a dividend?

Oncolys Biopharma Inc does not currently pay a dividend.

When does Oncolys Biopharma Inc next pay dividends?

Oncolys Biopharma Inc does not currently pay a dividend.

How do I buy Oncolys Biopharma Inc shares?

To buy shares in Oncolys Biopharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oncolys Biopharma Inc?

Shares in Oncolys Biopharma Inc are currently trading at ¥1660, giving the company a market capitalisation of £178.0m.

Where are Oncolys Biopharma Inc shares listed? Where are Oncolys Biopharma Inc shares listed?

Here are the trading details for Oncolys Biopharma Inc:

Country of listing: Japan
Exchange: TYO
Ticker Symbol: 4588
What kind of share is Oncolys Biopharma Inc?

Based on an overall assessment of its quality, value and momentum, Oncolys Biopharma Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oncolys Biopharma Inc share price forecast 2020?

We were not able to load any forecast data for Oncolys Biopharma Inc.

How can I tell whether the Oncolys Biopharma Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncolys Biopharma Inc. Over the past six months, the relative strength of its shares against the market has been -9.89%. At the current price of ¥1660, shares in Oncolys Biopharma Inc are trading at -7.4% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oncolys Biopharma Inc PE Ratio?

We were not able to find PE ratio data for Oncolys Biopharma Inc.

Who are the key directors of Oncolys Biopharma Inc?

Oncolys Biopharma Inc's management team is headed by:

Keiji Yoshimura - DRC
Yasuo Urata - PRE
Yasushi Rokutanda - MDR
Naoki Kobayashi - EDR
Yasunari Kashihara - OTH
Katsuyuki Nagai - NED
Fumio Urano - IND
Who are the major shareholders of Oncolys Biopharma Inc?

Here are the top five shareholders of Oncolys Biopharma Inc based on the size of their shareholding:

Credit Suisse Securities (Japan) Limited Research Firm
Percentage owned: 6.15% (882k shares)
Astellas Pharma Inc Corporation
Percentage owned: 5.07% (727k shares)
Urata (Yasuo) Individual Investor
Percentage owned: 3.27% (469k shares)
Chugai Pharmaceutical Co Ltd Corporation
Percentage owned: 3.19% (457k shares)
Wonik Cube Corp Corporation
Percentage owned: 3% (431k shares)
Similar to 4588
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.